SLN
ANALYST COVERAGE5 analysts
BUY
+764.8%upside to target
L $49.00
Med $55.00consensus
H $67.00
Buy
480%
Sell
120%
4 Buy (80%)0 Hold (0%)1 Sell (20%)
Full report →
Key MetricsTTM
Market Cap$299.46M
Revenue TTM$838.3K
Net Income TTM-$75.01M
Free Cash Flow-$65.67M
Gross Margin66.9%
Operating Margin-9267.5%
Net Margin-8948.4%
Return on Equity-107.2%
Return on Assets-65.2%
Debt / Equity0.00
Current Ratio9.83
EPS TTM$-1.59
PRICE
Prev Close
6.49
Open
6.50
Day Range6.28 – 6.73
6.28
6.73
52W Range4.19 – 8.40
4.19
8.40
52% of range
VOLUME & SIZE
Avg Volume
328.3K
FUNDAMENTALS
P/E Ratio
-3.9x
Not profitable
EPS (TTM)
Div Yield
No dividend
TECHNICAL
RSI (14)
42
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30

SLN News

About

silence therapeutics develops a new generation of medicines by harnessing the body’s natural mechanism of rna interference, or rnai, within its cells. our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic rna molecules exclusively to target cells. silence’s proprietary rna chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. for more information, visit us at www.silence-therapeutics.com

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Craig A. Tooman
Country
UK
Iain Gladstone RossInterim CEO & Chairman of the Board
Jaimin ShahSVP & General Counsel
GabrielChief Technical Operations Officer
Gem Gokmen HopkinsHead of IR & Corporation Communications
Gianine EspositoChief Human Resources Officer
Marie Wikstrom LindholmChief Scientific Officer
Rhonda L. HellumsExecutive VP, CFO, Secretary & Executive Director
Steven J. RomanoExecutive Vice President and Chief Research & Development Officer
Curtis RambaranChief Medical Officer